Please Wait
Applying Filters...
menu
    • menu
    IOL Chemicals is an innovation-driven bulk drug, Intermediate and Specialty Chemicals company.

    Virtual Booth

    Contact Supplier

    Alchem offers Botanical APIs for Pharmaceuticals, Cosmetics and Nutraceuticals// FDA-inspected and EU-GMP certified.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Repatha

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Amgen to Present Repatha Phase 3 Data at AHA Scientific Sessions
    Amgen to Present Repatha Phase 3 Data at AHA Scientific Sessions

    31 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/amgens-landmark-phase-3-repatha-data-to-be-presented-as-late-breaker-at-the-american-heart-association-scientific-sessions-2025-302600739.html

    PR NEWSWIRE
    31 Oct 2025
    Share Share
    AMGEN Launches REPATHA® DIRECT-TO-PATIENT PROGRAM IN U.S.
    AMGEN Launches REPATHA® DIRECT-TO-PATIENT PROGRAM IN U.S.

    06 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/amgen-makes-repatha-available-through-amgennow-a-direct-to-patient-program-in-the-us-302575486.html

    PR NEWSWIRE
    06 Oct 2025
    Share Share
    Amgen's Phase III Data Supports FDA Label Expansion Of Repatha
    Amgen's Phase III Data Supports FDA Label Expansion Of Repatha

    05 Oct 2025

    // INDPHARMAPOST

    https://www.indianpharmapost.com/news/amgens-phase-iii-data-supports-fda-label-expansion-of-repatha-17937

    INDPHARMAPOST
    05 Oct 2025
    Share Share
    FDA Expands Repatha Use to Adults at Risk of Cardiovascular Event
    FDA Expands Repatha Use to Adults at Risk of Cardiovascular Event

    28 Aug 2025

    // INDPHARMAPOST

    https://www.indianpharmapost.com/news/fda-expands-repatha-indication-to-adults-at-risk-of-major-cardiovascular-events-from-uncontrolled-ldl-c-17677

    INDPHARMAPOST
    28 Aug 2025
    Share Share
    Amgen Expands Repatha® Use for High Cardiovascular Risk in Adults
    Amgen Expands Repatha® Use for High Cardiovascular Risk in Adults

    25 Aug 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/repatha-now-indicated-for-adults-at-increased-risk-for-major-adverse-cardiovascular-events-due-to-uncontrolled-ldl-c-302537326.html

    PR NEWSWIRE
    25 Aug 2025
    Share Share
    Amgen’s Biologics Repatha Receives Suppl Approval in US
    Amgen’s Biologics Repatha Receives Suppl Approval in US

    21 Aug 2025

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125522

    FDA
    21 Aug 2025
    Share Share